Browsing Tag
crizotinib
3 posts
IDEAYA and Servier start Phase III adjuvant uveal melanoma study
IDEAYA and Servier have dosed the first patient in the 450-person OptimUM-11 Phase III study, extending darovasertib plus crizotinib into primary uveal melanoma before the combination’s metastatic indication has completed regulatory review.
IDEAYA Biosciences (IDYA) stock in focus as ASCO 2026 late-breaker sets up fuller OptimUM-02 readout
IDEAYA Biosciences heads to ASCO 2026 with full OptimUM-02 data. Read why the late-breaking slot could matter for IDYA stock and melanoma strategy.
ALTA-1L trial results : Takeda’s ALUNBRIG continues to show superiority over crizotinib
ALTA-1L trial results : Takeda Pharmaceutical says that ALUNBRIG (brigatinib), its tyrosine kinase inhibitor (TKI), is continuing to…